Lumen

Lumen's problem is that its one number may not matter enough. Dietitians and metabolism researchers have repeatedly questioned how much actionable signal a single morning breath CO2 reading carries — it is an indirect proxy influenced by the previous day's carbs, sleep, and measurement technique, and the company's own published evidence is retrospective and observational far more than interventional. The product is explicitly not a medical device and not FDA-cleared, which caps it to the wellness aisle just as the serious money in metabolic health migrates to clinical-grade tools. Commercially, the visible signals have gone quiet: no disclosed funding since December 2022, no headline partnerships, and a business model — a few-hundred-dollar device plus an ongoing subscription for a single-metric app — that sits precisely in the blast radius of subscription fatigue. The competitive environment worsened on every flank: OTC continuous glucose monitors deliver richer, continuous metabolic data at falling prices; Oura, Whoop, and Apple bundle metabolic and recovery insights into devices people already wear; and the GLP-1 wave Lumen hopes to ride arguably deflates it — patients getting 15–20% weight loss pharmacologically have less need for a carb-cycling coach, and the "GLP-1 companion" positioning is being contested by every player in digital health, from Noom to WeightWatchers to the drugmakers' own apps. Lumen's daily-ritual engagement model is also its churn risk: when the novelty of the morning breath fades, so does the subscription. A niche-loved device with contested science, three-plus years from its last round, is an acquisition candidate at best and a slow subscription melt at worst.